Our screening assay with 1535 well-characterised compounds also revealed that differentially expressed ERβ could be a potential target for E-cadherin-deficient DGC, and provided convincing evidence of clinical use of oestrogen drugs including mestranol for prevention and treatment of this subtype of GC. The gene discussed is CDH1; the disease is gastric cancer.